Kaltura Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Kaltura Inc trades at $1.32 (market cap $199.08M), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.64 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 11.4× Kaltura Inc's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals.
| KLTR | SLS | |
|---|---|---|
Market Cap | $199.08M | $2.27B |
Volume | 175,927 | 4,179,659 |
Sector | Technology | Health |
52-Week High | $1.89 | $15.46 |
52-Week Low | $1.08 | $1.39 |
Typical Hold Time | 21 Days | — |
Enterprise Value | $211.29M | $2.14B |
Signals from Pluang's Aura AI — not financial advice
Kaltura (KLTR) trades at $1.305, down 1.88% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $181M and net losses narrowing from -$68M in 2022 to -$12M in 2025. Recent positive developments include AI platform awards and major streaming deployments, though valuation metrics remain elevated with P/S of 1.08 and EV/EBITDA of 271.59.
The stock presents a turnaround story with improving profitability trends but faces significant execution risks. Analyst sentiment is mixed with 44% buy ratings, while technical indicators suggest near-term pressure. Key catalysts include AI product commercialization and further margin improvement, but high debt levels and persistent losses require careful monitoring.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →